GW Pharma's Cannabis-Derived Drug to be Reviewed by FDA

If approved, it could be the country's first cannabis-derived drug.


GW Pharmaceuticals said early Thursday that the Food and Drug Administration will review a new drug application for its cannabis-derived drug epidiolex for seizures associated with two rare types of childhood epilepsy.

RELATED: FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for CBD Oral Solution as Investigational Treatment for Prader-Willi Syndrome

Advertisment: Cannabis Business Times » Cannabis Business Times Best Cannabis Companies to Work For » CBT Best Companies 2026 ROS Parallax Reveal » bcc-ads-730x570
Advertisment: Cannabis Business Times » Cannabis Business Times Best Cannabis Companies to Work For » CBT Best Companies 2026 ROS Parallax Reveal » bcc-ads-730x570

The application was accepted for priority review, a special status that offers an accelerated review for high-priority products, and the regulator aims to have a decision by or on June 27, 2018. If approved, epidiolex -- which contains cannabidiol (CBD), rather than the psychoactive component of cannabis, THC -- could be the country's first cannabis-derived drug.

Advertisment: Frank Mayer » Frank Mayer Order 84 » CBT ROS Medium Rectangle 300x250 July 2025 » CBT Web Ad - July 2025

Read more

Advertisment: Hanwha Vision » Hanwha Vision Order 78 » CBT ROS 300x250 Medium Rectangle July 2025 » D53_Cannabis-Business-Times_300x250_v1
Advertisment: Frank Mayer » Frank Mayer Order 84 » CBT ROS Medium Rectangle 300x250 July 2025 » CBT Web Ad - July 2025
Page 1 of 487
Next Page
Advertisment: Greentank » Greentank Order 111 » CBT ROS Mobile Adhesion 360x120 July 2025 » GT AC ADS 600X200@2x